ArticleScientific reports2022
AXL/CDCP1/SRC axis confers acquired resistance to osimertinib in lung cancer.
Yuichi Murakami et al.PubMed ↗Full text ↗Publisher ↗
No numbers read from the abstract.
23 papers cite it
this papercites it
ArticleScientific reports2022
Yuichi Murakami et al.PubMed ↗Full text ↗Publisher ↗
No numbers read from the abstract.